Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 10/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.43 |
| ▸ | LOX | P28300 | 2/20 | 0.42 |
| ▸ | PNMT | P11086 | 2/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.40 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30152373 | 1.00 | DAO (0.48) | DAOIDO1CSNK2A1LOXL2LOX | |
| Hydrochloric Acid SCHEMBL30152380 | 0.98 | IDO1 (0.49) | DAOIDO1CSNK2A1LOXL2LOX | |
| SCHEMBL21540685 | 0.85 | TAAR1 (0.60) | DAOIDO1PNMTTAAR1MAOB | |
| SCHEMBL39753 | 0.84 | IDO1 (0.66) | IDO1CSNK2A1LOXL2LOXPNMT | |
| SCHEMBL4656217 | 0.82 | DAO (0.49) | DAOIDO1NOTUM | |
| SCHEMBL3717047 | 0.81 | TAAR1 (0.47) | DAOCSNK2A1PNMTTAAR1MAOB | |
| SCHEMBL8690013 | 0.81 | LOXL2 (0.47) | DAOIDO1LOXL2LOXTAAR1 | |
| SCHEMBL24400227 | 0.80 | DAO (0.48) | DAOIDO1NOTUM | |
| SCHEMBL1592495 | 0.80 | DAO (0.48) | DAOIDO1NOTUM | |
| SCHEMBL257057 | 0.80 | DAO (0.48) | DAOIDO1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | claimed |
| CN-117534631-A | Phenylthiazole amine PI4KIII beta inhibitor, preparation method, pharmaceutical composition and application thereof | 南京市鸿舜医药科技有限公司 | 2024-02-09 | — | — | CN | disclosed |
| US-20230021448-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-01-26 | — | — | US | disclosed |
| WO-2021067805-A1 | OXALAMIDE HETEROBYCYCLIC COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| EP-2462141-B1 | NOVEL AZAHETEROCYCLIC COMPOUNDS | MERCK PATENT GMBH (DE) | 2017-09-27 | — | — | EP | disclosed |
| US-9067951-B2 | Process and intermediates for the production of CCR2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| US-9067951-B2 | Process and intermediates for the production of CCR2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| US-9023847-B2 | Azaheterocyclic compounds | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-8962656-B2 | CCR2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-24 | — | — | US | disclosed |
| US-20140336374-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008118758-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (GB) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118758-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (GB) | 2008-10-02 | — | — | WO | disclosed |
| US-6756384-B2 | TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. | NOVO NORDISK A/S (DK) | 2004-06-29 | — | — | US | disclosed |
| US-20030135056-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2003-07-17 | — | — | US | disclosed |
| EP-1268484-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | EP | disclosed |
| US-6437147-B1 | FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM | NOVO NORDISK (DK) | 2002-08-20 | — | — | US | disclosed |
| US-20020058659-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2002-05-16 | — | — | US | disclosed |
| WO-2001068652-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336374-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS | CCR2, CCR5, CCR1 | DAO 2107/4885IDO1 357/4885CSNK2A1 1000/4885 |
| US-20030135056-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | DAO 1427/4885IDO1 48/4885CSNK2A1 1243/4885 |
| US-20020058659-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | DAO 1427/4885IDO1 48/4885CSNK2A1 1243/4885 |
| US-20230021448-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | DAO 4637/4885IDO1 1263/4885CSNK2A1 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.